Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. - Wikidata - wikimedia - TriplyDB

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.

http://www.wikidata.org/entity/Q33555296

about

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma Biliary tract cancers: SEOM clinical guidelines Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review.Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.

P2860

Q26852049-78C9A1C4-00F3-4FE8-B8EA-60D0DC091C20 Q31033443-56FCBB0E-BA65-4A0D-A0AC-22C20EB2A651 Q33428348-2D343DDA-26B7-4776-B641-F7297F809CC7 Q35078039-EBE6D449-812B-4135-8693-82772DF86A3F Q36400234-003F65CA-4AF2-408A-9C85-0B3A098ED6A7 Q39012507-55622BC7-B13B-4379-999C-A432836C8684 Q39022553-8DD306DE-9044-436A-8E25-FD772EE631CF Q39025911-F7E2E388-D6A8-4FE1-8E52-BA48454336BB Q40413628-C5B836AD-3BF0-4719-B410-7258E3B71AAD Q40860251-DCADC114-322D-4902-B857-139BE60C0E2B Q50077698-7108798F-CB1B-479A-BB6F-4E7D15528198 Q53579614-3CA5CC47-A1BC-4C10-A641-93A82FC28A53

P2860

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.

http://www.wikidata.org/entity/Q33555296

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Multivariate prognostic factor ...... advanced biliary tract cancer.

@ast

Multivariate prognostic factor ...... advanced biliary tract cancer.

@en

Multivariate prognostic factor ...... advanced biliary tract cancer.

@nl

type

label

Multivariate prognostic factor ...... advanced biliary tract cancer.

@ast

Multivariate prognostic factor ...... advanced biliary tract cancer.

@en

Multivariate prognostic factor ...... advanced biliary tract cancer.

@nl

prefLabel

Multivariate prognostic factor ...... advanced biliary tract cancer.

@ast

Multivariate prognostic factor ...... advanced biliary tract cancer.

@en

Multivariate prognostic factor ...... advanced biliary tract cancer.

@nl

P1433

Q33555296-79E8FD59-51E0-40B0-A38F-DD111F81A039

P1476

Q33555296-E9813F93-155E-428F-B211-BF9F553F2FBC

P2093

Q33555296-0134B63F-532B-45A7-9B38-67AB5AF16E9E

Q33555296-06B4BFEC-BA8C-4A78-8663-48EB63BB34D0

Q33555296-162B0840-CF7B-43AD-B7F0-58AA21FF9E18

Q33555296-1828707A-B17D-47C5-939C-20709FCD8D42

Q33555296-257DE223-1C27-49A8-B39A-6D74DF764106

Q33555296-31BE6B74-C03D-4F43-B92F-3C681F0714AF

Q33555296-59A15431-1FD5-4AAF-9146-E89C3C697BB5

Q33555296-73DE7B28-B442-45D7-82EF-A712D3493B87

Q33555296-7823BA9D-C69E-4DC0-824A-4DCBFA38EF65

Q33555296-78F0639B-EB5E-419E-A18B-90F989A20E9E

P2860

Q33555296-162E568D-9958-4942-A7CA-F6F0C75499B8

Q33555296-46883425-CD2B-47BB-987D-41050FE41868

Q33555296-5946A969-FB31-4ED5-9320-86C026C37961

Q33555296-60D778E6-8DC7-4D36-B1D4-C2933F9A1607

Q33555296-778EE7DA-F1C6-4357-B862-46DA223F7572

Q33555296-8E8E8C68-760A-42E9-84E4-5DF0626E9732

Q33555296-A9E3B15C-DD19-4FBA-A430-4D3AE7C77F3D

Q33555296-B24C97B5-3F97-45C0-83ED-B818B25B7730

Q33555296-B9D56EE6-025D-49BA-80EA-C3316645FA50

Q33555296-C2B59B05-1197-4AB6-BBF1-22631954753D

P2888

Q33555296-4B7D160C-D989-4C9C-BF6E-37ED4F323037

P304

Q33555296-0F249591-6E6C-4F75-AB87-1DB6C73A267D

P31

Q33555296-07836CB5-2BE8-4836-A68D-4E643DA59B08

P356

Q33555296-A15AEF6C-0224-4FB7-BF0D-541586EF5601

P407

Q33555296-D6942C9B-523B-40B6-B0D3-BF1EB3BEE648

P433

Q33555296-6FBCF781-5F81-43EA-ACB9-5FE9A82479BC

P478

Q33555296-0E3FE095-C5DC-409D-8065-326E40E66004

P50

Q33555296-0D54D4FE-EDB0-43DD-B314-3AE9D7DC4FEE

Q33555296-4436E01B-8FC0-48F2-A2FD-1E32CE3D19D8

Q33555296-802DDBB7-927D-44E0-A697-8CABCEEE4776

Q33555296-957D961D-B6E7-40FB-831F-AAEB54BC66D2

Q33555296-95EA3D1A-1DA1-442A-AFDF-0A48EAB58B0D

Q33555296-9A235BBE-4410-4C29-9B89-474396860363

Q33555296-BACCF67F-2101-4117-83B9-387834DBA85F

Q33555296-C93F9327-AF6A-4783-AFFA-351E635779F8

Q33555296-EBB6EE15-DEB2-41AF-9D02-4C2B636B4399

Q33555296-FBDBE7E1-4CA0-4F49-8951-D9ADE04992EB

P577

Q33555296-7423B65D-3601-4E00-A068-4D1DAE947AA5

P5875

Q33555296-3C9DEC7A-3D11-4C2A-A805-CAF446DC15C3

P6179

Q33555296-EC114697-F512-4080-BA1D-C5B621EA381A

P698

Q33555296-6B2B9B6D-7803-4C60-9D61-60D26AD58B15

P921

Q33555296-6BDF12A6-C8CB-4FEB-A9FB-F263F5E6E16E

P932

Q33555296-6DD7502C-98BA-4DFE-B843-58E38565C65B

P356

P1433

British Journal of Cancer

P1476

Multivariate prognostic factor ...... advanced biliary tract cancer

@en

P2093

A E Brunetti

http://www.w3.org/2001/XMLSchema#string

E Vasile

http://www.w3.org/2001/XMLSchema#string

F Leone

http://www.w3.org/2001/XMLSchema#string

G Aprile

http://www.w3.org/2001/XMLSchema#string

G Brandi

http://www.w3.org/2001/XMLSchema#string

G Fasola

http://www.w3.org/2001/XMLSchema#string

J Corbelli

http://www.w3.org/2001/XMLSchema#string

M A Barbera

http://www.w3.org/2001/XMLSchema#string

M Milella

http://www.w3.org/2001/XMLSchema#string

M Reni

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

Biliary tract cancers.

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.

Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.

Role of chemotherapy in treatments for biliary tract cancer.

Biliary tract carcinomas: from chemotherapy to targeted therapy.

P2888

P304

2165-2169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.190

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

Lorenzo Fornaro

Alfredo Falcone

Francesca Bergamo

Vittorina Zagonel

Caterina Vivaldi

P577

2014-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261516369

http://www.w3.org/2001/XMLSchema#string

P6179

1040427383

http://www.w3.org/2001/XMLSchema#string

P698

24714745

http://www.w3.org/2001/XMLSchema#string

P921

P932

4007244

http://www.w3.org/2001/XMLSchema#string